Ani Pharmaceuticals (ANIP) Common Equity (2010 - 2026)
Ani Pharmaceuticals (ANIP) posted Common Equity of $562.3 million for Q1 2026, up 3.99% sequentially from $540.7 million in Q4 2025, and up 761.5% YoY from $65.3 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Common Equity (2010 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at $562.3 million in Q1 2026.
- Quarterly Common Equity rose 761.5% year-over-year to $562.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $562.3 million (up 761.5% YoY) and the FY2025 annual result came in at $540.7 million, up 2669.98% from the prior year.
- Common Equity advanced to $562.3 million in Q1 2026 per ANIP's latest filing, from $540.7 million in the prior quarter.
- Over five years, Common Equity peaked at $562.3 million in Q1 2026 and troughed at -$85.0 million in Q1 2025.
- A 5-year average of $165.1 million and a median of $2000.0 in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 758.55% in 2023, then jumped 52362700.0% in 2024.
- Over 5 years, Common Equity stood at $12.2 million in 2022, then sank by 758.55% to -$80.1 million in 2023, then soared by 73.74% to -$21.0 million in 2024, then jumped by 2669.98% to $540.7 million in 2025, then gained by 3.99% to $562.3 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $562.3 million, $540.7 million, and $505.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.28 Bn | 165.89 Mn | 597.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 597.21 Mn |
| Mar 31, 2026 | 562.30 Mn |
| Dec 31, 2025 | 540.72 Mn |
| Sep 30, 2025 | 505.82 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | -85.00 Mn |
| Dec 31, 2024 | -21.04 Mn |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | -65.03 Mn |
| Mar 31, 2024 | 523.63 Mn |
| Dec 31, 2023 | -80.13 Mn |
| Sep 30, 2023 | 506.51 Mn |
| Jun 30, 2023 | 495.49 Mn |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | 12.17 Mn |
| Sep 30, 2022 | -4.98 Mn |
| Jun 30, 2022 | -83.63 Mn |
| Mar 31, 2022 | -4.25 Mn |
| Dec 31, 2021 | -3.06 Mn |
| Sep 30, 2021 | -4.24 Mn |